Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Approvals/Philippines FDA/Timoptol

Approved

STANDARD

Timoptol

Laboratories Merck Sharp & Dohme-Chibret🇵🇭 Food and Drug Administration - Philippines

Approval Date: Jul 14, 2025
Approval ID: 4eb03246099da115
Company: Laboratories Merck Sharp & Dohme-Chibret
Type: Standard

Approval Details

Approval Id: 4eb03246099da115
Drug Approval Philippines Name: Timoptol
Product Name: Timoptol
Registration Number: DR-X6980
Brand Name: Timoptol
Generic Name: Timolol maleate
Dosage Form: Sterile Ophthalmic Solution
Dosage Strength: 5 mg/ mL (0.5% w/v)
Manufacturer: Laboratories Merck Sharp & Dohme-Chibret
Importer: Santen Philippines Inc.
Issuance Date: 25 May 2025
Expiry Date: 02 August 2031
Pharmacologic Category: Anti-glaucoma (Beta Blocking Agent)
Classification: Prescription Drug (RX)

Active Ingredients

Approved

Quick Info

Agency

Philippines FDA

Country

🇵🇭

Approval Date

Jul 14, 2025

Approval ID

4eb03246099da115

Type

Standard

Back to Philippines FDA Approvals

Timoptol - Philippines FDA Drug Approval Details